GlassScriptPhysician profile
April Soleim
NPI 1538833918
$1,674.27
in general payments reported to CMS, 2019-2025
14 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.99 · 2023: $865 · 2024: $557 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.30 | 2023-2025 | |
| Corium, LLC | $203.52 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $177.01 | 2023-2024 | Auvelity |
| Alkermes, INC. | $150.37 | 2021-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $117.30 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $101.64 | 2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $93.26 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.10 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $34.93 | 2023-2025 | Trintellix |
| Noven Therapeutics, LLC | $16.96 | 2023 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $16.84 | 2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $15.92 | 2024 | Fanapt |
| Vertical Pharmaceuticals, LLC | $15.41 | 2025 | Relexxii |
| Supernus Pharmaceuticals, INC. | $14.71 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Soleim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.